Back to search

University of Crete (UOC)

Μελέτη της δράσης των ενδογενών και συνθετικών νευροστεροειδών στον πόνο

Abstract

dc:description

Although pain is described as an unpleasant, with serious consequences for the individual experience, it can be vital since in many cases it warns of the existence of significant damage. According to Woolf (Woolf, 2010) pain can be divided into nociceptive, neuropathic and inflammatory. In the present study we focused on inflammatory pain which is a consequence of various pathological conditions such as viral or bacterial infection, tissue injury or autoimmune diseases. The main feature of inflammatory pain is the activation of the immune system which aims to repair the injured tissue or inhibit the infection. Dehydroepiandrosterone (DHEA) is a steroid hormone derived from adrenal glands with strong neuroprotective and immunomodulatory properties. DHEA is also produced and acts in the brain and other structures of the nervous system. DHEA has a wide range of actions including its beneficial effect on pain. DHEA acts by interacting with both cytoplasmic and membrane receptors, including neurotrophin receptors TrkA and p75NTR. However, DHEA is rapidly metabolized into androgens and estrogens, which limits its therapeutic use. For this reason, new molecules have been developed similar to DHEA, which retain its beneficial effects but lack its ability to be metabolized to sex hormones. Recent studies have shown that the analog of DHEA, BNN27, binds to neurotrophin receptors. BNN27 has neuroprotective properties preventing neuronal apoptosis, additionally to its strong immunomodulatory properties, affecting, among other things, the production and release of inflammatory molecules. Based on the above, the purpose of this study was to evaluate the role of BNN27 on inflammatory pain. For this purpose, the model of inflammatory hyperalgesia caused by induction of inflammation and the application of a thermal stimulus at the site of inflammation in wild-type mice was applied. Inflammation and swelling in mice were induced by intraplantar administration of Complete Freund's Adjuvant, CFA, and BNN27 was administered at different concentrations (10, 50, 100 mg/ kg) and intervals. Threshold of inflammatory hyperalgesia, the size of edema and the expression of factors that contribute / participate in pain process were then assessed. Our results showed that BNN27 increases the inflammatory pain threshold without affecting edema. In addition, it induces the release of inflammatory agents (IL-6, TNF-α, IL-10, NGF, iNOS) 6 hours following the induction of inflammation, a phenomenon that subsides within 24 hours from the onset of the inflammatory response. In addition, BNN27 stimulates the synthesis of opioid peptides and μ opioid receptor in the inflamed paw. Opioid peptides and their receptors seem to mediate the action of BNN27 on pain since pharmacological inhibition of opioid receptors reduces the analgesic effect of BNN27 in a significant way. The mechanism of action of BNN27 also includes the reduction of nerve growth factor (NGF) mRNA levels in the dorsal root ganglia (DRGs), in which the latter acts by enhancing the transmission of pain signals to the brain, and activation of the TrkA receptor and the downstream AKT2 signaling pathway. Finally, we studied the effect of BNN27 on T-lymphocytes in vitro. T-lymphocytes are involved in the inflammatory process since they release pro-inflammatory cytokines and opioid peptides at the site of inflammation. We found that different concentrations of BNN27 (10-6, 10-7 and 10-8 M) affect T-lymphocyte proliferation and survival in a different way. Indeed, BNN27 at the concentration of 10-7 M increases the proliferation rate of T-lymphocytes in contrast to concentrations of 10-6 Μ and 10-8 M that decrease their proliferation rate. Co-administration of BNN27 at a concentration of 10-8 M with a TrkA receptor inhibitor (10-6 M) further reduces T-lymphocyte proliferation rate. Finally, BNN27 stimulates the release of cytokines and opioid peptides from T-lymphocytes, while co-administration with the TrkA inhibitor inhibits this effect. In conclusion, our results demonstrate that BNN27 has a beneficial effect on inflammatory hyperalgesia. The action of BNN27 is mediated by the TrkA receptor and involves the inhibition of NGF synthesis in DRGs. In addition, its mechanism of action includes the inhibition of cytokine release and the induction of opioid peptides synthesis in the inflamed tissue, most likely by T-lymphocytes, as BNN27 affects the proliferation rate and the release of these cytokines and opioid peptides from this cell type.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Poulaki, Smaragda
  • Πουλάκη, Σμαράγδα

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51588

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Poulaki, Smaragda; Πουλάκη, Σμαράγδα. Μελέτη της δράσης των ενδογενών και συνθετικών νευροστεροειδών στον πόνο. University of Crete (UOC), 2022. http://hdl.handle.net/10442/hedi/51588